Lemtrada Stroke Injury & FDA Warning
Cincinnati Pharmaceutical Attorney and Ohio Product Liability Lawyer reviewing Lemtrada stroke injury cases for plaintiffs nationwide
The U.S. Food and Drug Administration (FDA) has issued a warning about the risk of stroke and tears to the wall of arteries in the head and neck following the use of Lemtrada.
Medical reports received by the FDA indicate that schemic and hemorrhagic stroke and cervicocephalic arterial dissection have occurred after MS patients received a regular dose of Lemtrada (alemtuzumab, Sanofi Genzyme). The health safety agency notes that stroke injury and tears in arteries can lead to disability and death.
The FDA warning was released after 13 Lemtrada stroke injury cases were reported to the FDA since 2014. The MS medication now has added the injury risk to the Boxed Warning, prescribing information and patient Medication Guide.
The agency has also updated the drug label of Campath. The FDA warning outlines symptoms of stroke and tears to the walls of arteries that patients and caregivers should be aware of, which can include:
- Sudden numbness or weakness in the face, arms, or legs, especially if it occurs on only one side of the body
- Sudden confusion, trouble speaking, or difficulty understanding speech
- Sudden trouble seeing in one or both eyes
- Sudden trouble with walking, dizziness, or loss of balance or coordination
- Sudden severe headache or neck pain
Joe Lyon is a highly-rated Ohio Product Liability Attorney and Pharmaceutical Defect Lawyer investigating cases of stroke injury for plaintiffs nationwide.
Lemtrada Stroke Injury Risk & MS Patients
Prescribers of Lemtrada are advised to inform patients before each infusion to seek immediate emergency medical attention if they experience any symptoms related to stroke or artery tears.
Cases of Stroke Injury are rare, but very severe. Most patients who developed stroke or tears in artery linings developed symptoms within one day of receiving Lemtrada.
The FDA warns that diagnosis is often complicated because early symptoms such as headache and neck pain are non-specific. Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.
The progress, severity and specific symptoms of MS in any one person cannot yet be predicted. MS affects more than 2.3 million people worldwide.
If you or a loved one has suffered an injury due to Lemtrada use, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403.
You will speak directly with Mr. Lyon, and he will help you answer critical questions regarding stroke injury risks.